283 related articles for article (PubMed ID: 32117845)
1. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.
Czech M; Baran-Kooiker A; Atikeler K; Demirtshyan M; Gaitova K; Holownia-Voloskova M; Turcu-Stiolica A; Kooiker C; Piniazhko O; Konstandyan N; Zalis'ka O; Sykut-Cegielska J
Front Public Health; 2019; 7():416. PubMed ID: 32117845
[No Abstract] [Full Text] [Related]
2. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
3. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
5. Rare diseases and orphan drugs: Latvian story.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
[TBL] [Abstract][Full Text] [Related]
6. Review of 11 national policies for rare diseases in the context of key patient needs.
Dharssi S; Wong-Rieger D; Harold M; Terry S
Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A
Front Pharmacol; 2018; 9():795. PubMed ID: 30079023
[No Abstract] [Full Text] [Related]
8. Tackling rare diseases at European level: why do we need a harmonized framework?
Taruscio D; Trama A; Stefanov R
Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471
[TBL] [Abstract][Full Text] [Related]
9. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
10. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Blankart CR; Stargardt T; Schreyögg J
Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
[TBL] [Abstract][Full Text] [Related]
11. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
12. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
13. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
14. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
Malinowski KP; Kawalec P; Trąbka W; Czech M; Petrova G; Manova M; Savova A; Draganić P; Vostalová L; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Front Pharmacol; 2019; 10():487. PubMed ID: 31139080
[TBL] [Abstract][Full Text] [Related]
15. Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries.
Stawowczyk E; Malinowski KP; Kawalec P; Bobiński R; Siwiec J; Panteli D; Eckhardt H; Simoens S; Agusti A; Dooms M; Pilc A
Front Pharmacol; 2019; 10():1279. PubMed ID: 31827433
[No Abstract] [Full Text] [Related]
16. Transposition and implementation of EU rare disease policy in Eastern Europe.
Pejcic AV; Iskrov G; Raycheva R; Stefanov R; Jakovljevic MM
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):557-566. PubMed ID: 28975845
[TBL] [Abstract][Full Text] [Related]
17. Access to orphan drugs - comparison across Balkan countries.
Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
[TBL] [Abstract][Full Text] [Related]
18. The reimbursement of the expenses for medical treatment received by 'transnational' patients in EU-countries.
Kesteloot K; Pocceschi S; van der Schueren E
Health Policy; 1995 Jul; 33(1):43-57. PubMed ID: 10172359
[TBL] [Abstract][Full Text] [Related]
19. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
[TBL] [Abstract][Full Text] [Related]
20. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
